Viking Therapeutics Files 8-K Report

TL;DR

Viking Therapeutics filed an 8-K on Feb 28, 2024, covering material agreements and other events.

AI Summary

On February 28, 2024, Viking Therapeutics, Inc. filed an 8-K report detailing several events. The company entered into a material definitive agreement and reported other events, alongside the filing of financial statements and exhibits. The report was filed on March 1, 2024.

Why It Matters

This 8-K filing indicates significant corporate actions and disclosures by Viking Therapeutics, Inc., which could impact investors' understanding of the company's current status and future prospects.

Risk Assessment

Risk Level: low — This filing is a standard corporate disclosure and does not inherently present new risks.

Key Players & Entities

• Viking Therapeutics, Inc. (company) — Registrant
• February 28, 2024 (date) — Date of earliest event reported
• March 1, 2024 (date) — Filing date
• 9920 Pacific Heights Blvd, Suite 350, San Diego, CA 92121 (address) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.00001 — ch Registered Common Stock, par value $0.00001 per share VKTX The Nasdaq Stock Mar
• $85.00 — n Stock"). The public offering price is $85.00 per share of Common Stock and the Under
• $80.305705 — he Underwriting Agreement at a price of $80.305705 per share. Under the terms of the Under
• $550.0 million — from the Offering will be approximately $550.0 million (excluding any sale of shares of Common

Filing Documents

• vktx-20240228.htm (8-K) — 55KB
• vktx-ex1_1.htm (EX-1.1) — 313KB
• vktx-ex5_1.htm (EX-5.1) — 13KB
• vktx-ex99_1.htm (EX-99.1) — 19KB
• img201808844_0.jpg (GRAPHIC) — 11KB
• img246856755_0.jpg (GRAPHIC) — 6KB
• 0000950170-24-023838.txt ( ) — 605KB
• vktx-20240228.xsd (EX-101.SCH) — 30KB
• vktx-20240228_htm.xml (XML) — 5KB

01. Entry into a Material Definitive Agreement

Item 1.01. Entry into a Material Definitive Agreement. On February 28, 2024, Viking Therapeutics, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Morgan Stanley & Co. LLC and Leerink Partners LLC (the "Representatives"), as representatives of the several underwriters named therein (the "Underwriters"), relating to an underwritten public offering (the "Offering") of 6,471,000 shares of the Company's common stock ("Common Stock"). The public offering price is $85.00 per share of Common Stock and the Underwriters have agreed to purchase the Common Stock pursuant to the Underwriting Agreement at a price of $80.305705 per share. Under the terms of the Underwriting Agreement, the Company also granted to the Underwriters an option, exercisable in whole or in part at any time for a period of 30 days from the date of the Underwriting Agreement, to purchase up to an additional 970,650 shares of Common Stock at the public offering price. The Offering is being made pursuant to the Company's automatic shelf registration statement on Form S-3 (File No. 333-273460), previously filed with the Securities and Exchange Commission (the "SEC") on July 26, 2023 and which automatically became effective upon filing, a base prospectus dated July 26, 2023 and a prospectus supplement dated February 28, 2024. Gross proceeds from the Offering will be approximately $550.0 million (excluding any sale of shares of Common Stock pursuant to the Underwriters' option to purchase additional shares), before deducting underwriting discounts and commissions and estimated Offering expenses payable by the Company. The Company currently intends to use the net proceeds from the Offering for continued development of its VK2809, VK2735 and VK0214 programs and for general research and development, working capital and general corporate purposes. The purchase and sale of the Common Stock, and the closing of the Offering, is expected to take place on or about Ma

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements that involve risks and uncertainties, such as statements related to the anticipated closing of the Offering and the anticipated use of proceeds from the Offering. The risks and uncertainties involved include the Company's ability to satisfy certain conditions to closing the Offering on a timely basis or at all, market and other conditions, and other risks detailed from time to time in the Company's periodic reports and other filings with the SEC. You are cautioned not to place undue reliance on forward-looking statements, which are based on the Company's current expectations and assumptions and speak only as of the date of this Current Report on Form 8-K. The Company does not intend to revise or update any forward-looking statement in this Current Report on Form 8-K as a result of new information, future events or otherwise, except as required by law.

01. Other Events

Item 8.01. Other Events. On February 28, 2024, the Company issued a press release announcing the pricing of the Offering. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 1.1 Underwriting Agreement, dated as of February 28, 2024, by and among Viking Therapeutics, Inc. and Morgan Stanley & Co. LLC and Leerink Partners LLC, as representatives of the underwriters named therein. 5.1 Opinion of Paul Hastings LLP. 23.1 Consent of Paul Hastings LLP (included in Exhibit 5.1). 99.1 Press Release, dated February 28, 2024. 104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VIKING THERAPEUTICS, INC. Date: March 1, 2024 By: /s/ Brian Lian, Ph.D. Brian Lian, Ph.D. President and Chief Executive Officer (Principal Executive Officer)

View Full Filing

View this 8-K filing on SEC EDGAR